

July 30, 2026 06:02 PM GMT

Realtek Semiconductor | Asia Pacific

Better than feared outlook

AlphaSignals Earnings Reaction

Unchanged Impact to our thesis	↓ Modest shortfall Financial results versus consensus	↓ Modest revision lower Direction of next 12-month consensus EPS
--	---	--

Source: Company data, Morgan Stanley Research

The stock appears to be a safe harbor vs. other high-flyers (e.g., Memory) following the trough into 2Q earnings .

Key Takeaways

- 2Q GM missed, but a price increase to take effect in 3Q should help with GM recovery.
- Near-term clients need to build up inventory due to FOMP (fear of missing procurement).
- Our EW rating reflects limited cloud AI exposure, but we view downside as limited as well.

2Q review: 2Q revenue was NT\$37.6bn, +3% Q/Q and +18% Y/Y, 3% above MSe. 2Q gross profit was NT\$17.7bn. GM was 47.0%, -2.7ppt Q/Q and -3.2ppt Y/Y, 2.7ppt below MSe. EPS was NT\$7.42, -12% Q/Q and -3% Y/Y, 12% below MSe. Margin compression was driven by elevated memory pricing and constrained OSAT capacity.

2H26 outlook: PC segment faces demand pressure in 2H26 due to elevated memory costs and CPU supply tightness, but revenue growth is expected, helped by spec-up demand. For the consumer segment, TV shipments have begun to soften after FIFA; home appliance demand continues to grow steadily and global game console shipments are expected to fall this year. The networking segment demonstrated demand stability, supported by enterprise infra refresh cycles and the transition toward higher-value WiFi7 and multi-gig Ethernet solutions. The auto segment is expected to be seasonally strong in 2H, especially helped by growth from the European market.

Other highlights: Increased product pricing with certain customers is to take effect in 3Q, helping GM recover. Realtek is gaining share in the managed switch market, having increased 2-3ppt vs the previous reporting period. WiFi7 penetration in notebooks is estimated to reach ~30% this year, while WiFi8 deployment is seen starting from 1Q28.

Remain EW: The company is indeed showing better than feared outlook due to FOMP ([link](#)). We believe the stock is fairly valued relative to our implied target of 19x 2026E P/E. Supply constraints and weak end-market demand continues, but we expect the company to manage some revenue growth in 3Q and a continued GM rebound in 2H, helped by spec-up demand and price increases.

MORGAN STANLEY TAIWAN LIMITED+

Daniel Yen, CFA

Equity Analyst
Daniel.Yen@morganstanley.com +886 2 2730-2863

Charlie Chan

Equity Analyst
Charlie.Chan@morganstanley.com +886 2 2730-1725

MORGAN STANLEY ASIA LIMITED+

Daisy Dai, CFA

Equity Analyst
Daisy.Dai@morganstanley.com +852 2848-7310

MORGAN STANLEY TAIWAN LIMITED+

Tiffany Yeh

Equity Analyst
Tiffany.Yeh@morganstanley.com +886 2 7712-3032

Lucas Wang

Research Associate
Lucas.Wang@morganstanley.com +886 2 2730-2875

MORGAN STANLEY ASIA LIMITED+

Ethan Jia

Research Associate
Ethan.Jia@morganstanley.com +852 3963-2287



Realtek Semiconductor (2379.TW, 2379 TT)

Greater China Technology Semiconductors | Taiwan

Stock Rating	Equal-weight
Industry View	Attractive
Price target	NT\$717.00
Up/downside to price target (%)	3
Shr price, close (Jul 30, 2026)	NT\$697.00
52-Week Range	NT\$970.00-438.00
Sh out, dil, curr (mn)	513
Mkt cap, curr (mn)	NT\$357,466
Avg daily trading value (mn)	NT\$2,091

Fiscal Year Ending	12/25	12/26e	12/27e	12/28e
EPS (NT\$)**	28.77	37.49	37.48	43.56
EPS (NT\$)§	29.00	32.47	36.89	42.33
Revenue, net (NT\$ mn)	122,706	152,532	149,558	160,626
EBITDA (NT\$ mn)	18,079	21,468	22,519	26,821
ModelWare net inc (NT \$ mn)	14,753	19,230	19,224	22,339
P/E	17.0	18.6	18.6	16.0
ROE (%)	27.9	36.8	32.4	35.5

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Div yld (%)	4.8	4.4	4.4	0.0
-------------	-----	-----	-----	-----

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework
** = Based on consensus methodology
§ = Consensus data is provided by Refinitiv Estimates
e = Morgan Stanley Research estimates

Estimate revisions and quarterly financials

We cut our EPS estimates by 12% each for 2026 and 2027 EPS, and raise 2028 by 1%:

For 2026-27, we factor in actual 2Q26 results, near-term end demand weakness and supply constraints. We expect some demand recovery and supply relief into 2028.

Exhibit 1: Realtek: Estimate revisions

(NT\$ mn)	New '26e	Old '26e	Diff.	New '27e	Old '27e	Diff.	New '28e	Old '28e	Diff.
Net sales	152,532	156,709	-3%	149,558	160,658	-7%	160,626	162,724	-1%
COGS	78,947	79,554		75,202	82,304		80,848	83,198	
Gross profit	73,585	77,155	-5%	74,356	78,354	-5%	79,777	79,526	0%
Operating expenses	53,699	54,021		53,467	54,415		54,635	54,684	
Operating profit	19,886	23,134	-14%	20,889	23,939	-13%	25,142	24,841	1%
Non-op. income (exp.)	2,514	2,517		1,727	1,731		1,139	1,143	
Pretax income	22,400	25,650	-13%	22,616	25,669	-12%	26,282	25,984	1%
Taxes	3,170	3,749		3,392	3,850		3,942	3,898	
Net income	19,230	21,902	-12%	19,224	21,819	-12%	22,339	22,086	1%
Reported EPS	37.49	42.71	-12%	37.48	42.54	-12%	43.56	43.06	1%
Margins									
Gross margin	48.2%	49.2%	-1.0%	49.7%	48.8%	0.9%	49.7%	48.9%	0.8%
Operating margin	13.0%	14.8%	-1.7%	14.0%	14.9%	-0.9%	15.7%	15.3%	0.4%
Pretax margin	14.7%	16.4%	-1.7%	15.1%	16.0%	-0.9%	16.4%	16.0%	0.4%
Net margin	12.6%	14.0%	-1.4%	12.9%	13.6%	-0.7%	13.9%	13.6%	0.3%
Opex %	35.2%	34.5%	0.7%	35.7%	33.9%	1.9%	34.0%	33.6%	0.4%

Source: Company data, Morgan Stanley Research (e) estimates

Exhibit 2: Realtek: Quarterly financial statements

(NT\$ mn)	1Q26	2Q26p	3Q26e	4Q26e	1Q27e	2Q27e	3Q27e	4Q27e	1Q28e	2Q28e	3Q28e	4Q28e	2025	2026e	2027e	2028e
Total Revenues	36,423	37,553	39,615	38,184	35,322	38,427	40,836	34,973	36,728	39,669	42,354	41,875	122,706	152,532	149,558	160,626
Sequential Change	38.6%	3.1%	5.5%	-3.6%	-7.5%	8.8%	6.3%	-14.4%	5.0%	8.0%	6.8%	-1.1%				
Change vs Year Ago	4.0%	17.7%	34.3%	45.3%	-3.0%	2.3%	3.1%	-8.4%	4.0%	3.2%	3.7%	19.7%	8.2%	24.3%	-1.9%	7.4%
Cost of Sales	18,336	19,902	20,564	19,388	17,794	19,353	20,580	17,474	18,472	20,094	21,318	20,965	61,333	78,947	75,202	80,848
Percent of Revenues	50%	53%	52%	51%	50%	50%	50%	50%	50%	51%	50%	50%	50%	52%	50%	50%
Gross Profit	18,087	17,651	19,052	18,795	17,528	19,074	20,256	17,499	18,256	19,575	21,036	20,910	61,374	73,585	74,356	79,777
Percent of Revenues	49.7%	47.0%	48.1%	49.2%	49.6%	49.6%	49.6%	50.0%	49.7%	49.3%	49.7%	49.9%	50.0%	48.2%	49.7%	49.7%
Incremental Margin	54%	-39%	68%	NM	NM	50%	49%	NM	43%	45%	54%	NM	45%	41%	NM	49%
Total Opex	13,755	13,926	13,554	12,463	13,500	14,054	13,724	12,188	13,641	14,198	13,897	12,899	47,014	53,699	53,467	54,635
Percent of Revenues	37.8%	37.1%	34.2%	32.6%	38.2%	36.6%	33.6%	34.9%	37.1%	35.8%	32.8%	30.8%	38.3%	35.2%	35.7%	34.0%
Operating Income	4,332	3,725	5,497	6,332	4,027	5,020	6,532	5,310	4,615	5,377	7,139	8,011	14,360	19,886	20,889	25,142
Percent of Revenues	11.9%	9.9%	13.9%	16.6%	11.4%	13.1%	16.0%	15.2%	12.6%	13.6%	16.9%	19.1%	11.7%	13.0%	14.0%	15.7%
Total Non-operating Income (Loss)	646	645	645	579	432	432	432	432	285	285	285	285	2,901	2,514	1,727	1,139
Profit Before Taxes	4,977	4,370	6,142	6,911	4,459	5,451	6,964	5,742	4,900	5,661	7,424	8,296	17,261	22,400	22,616	26,282
Percent of Revenues	14%	12%	16%	18%	13%	14%	17%	16%	13%	14%	18%	20%	14%	15%	15%	16%
Taxes	648	565	921	1,037	669	818	1,045	861	735	849	1,114	1,244	2,507	3,170	3,392	3,942
Tax Rate	13.0%	12.9%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	14.5%	14.2%	15.0%	15.0%
Reported Income (TW GAAP)	4,330	3,805	5,221	5,874	3,790	4,634	5,919	4,881	4,165	4,812	6,310	7,052	14,753	19,230	19,224	22,339
Percent of Revenues	11.9%	10.1%	13.2%	15.4%	10.7%	12.1%	14.5%	14.0%	11.3%	12.1%	14.9%	16.8%	12.0%	12.6%	12.9%	13.9%
Change vs Year Ago	-9%	-3%	52%	121%	-12%	22%	13%	-17%	10%	4%	7%	44%	-4%	30%	0%	16%
Reported EPS (NT\$, TW GAAP)	8.44	7.42	10.18	11.45	7.39	9.03	11.54	9.52	8.12	9.38	12.30	13.75	28.77	37.49	37.48	43.56
Change vs Year Ago	-9%	-3%	52%	121%	-12%	22%	13%	-17%	10%	4%	7%	44%	-4%	30%	0%	16%

Source: Company data, Morgan Stanley Research (e) estimates

Valuation methodology

Our PT is unchanged at NT\$717: We factor in changes to our earnings estimates while keeping other parameters in our residual income model unchanged. We maintain our assumptions for cost of equity of 9.6%, intermediate growth rate of 7.3%, payout ratio of 79%, and terminal growth of 4.5%. Our bull and bear case scenario values are both unchanged at NT\$1117 and NT\$517, respectively.

Exhibit 3: Realtek: RI model


(NT\$ mn)	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e
Total Equity	59,382	62,887	69,512	76,394	83,775	91,693	100,185	109,293	119,063	129,542	140,782
Net Profit	19,230	19,224	22,339	23,961	25,701	27,567	29,568	31,715	34,017	36,487	39,136
ROAE	34.5%	31.4%	33.7%	32.8%	32.1%	31.4%	30.8%	30.3%	29.8%	29.4%	29.0%
Residual Income	12,985	12,976	15,189	16,163	17,188	18,286	19,463	20,725	22,077	23,527	25,081
Spread	24.9%	21.9%	24.2%	23.3%	22.5%	21.8%	21.2%	20.7%	20.2%	19.8%	19.4%
Ending Equity Capital	59,382										
PV of Forecast Period	103,318										
PV of Continuing Value	205,035										
Equity Value	367,734										
No. of Shares	513										
Projected Price	717										

Source: Company data, Morgan Stanley Research (e) estimates

Relative valuation

The current stock price implies 18.6x 2026e P/E, roughly in line with the historical average, given weakness in the PC end-market arising from elevated component costs. We view this as fair relative to our implied target P/E of 19.1x.

Exhibit 4: Realtek: Historical P/E



Source: Factset, Morgan Stanley Research estimates

Risk Reward – Realtek Semiconductor (2379.TW)

Better than feared outlook; EW

PRICE TARGET NT\$717.00


Base case, residual income model. We assume a cost of equity of 9.6%, an intermediate growth rate of 7.3%, payout ratio of 79%, and terminal growth rate of 4.5%.

Consensus Price Target Distribution

Source: Refinitiv, Morgan Stanley Research



RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research

EQUAL-WEIGHT THESIS

- Supply constraints and weak end-market demand continue, but we expect the company to manage some revenue growth in 3Q and a continued GM rebound in 2H, helped by spec-up demand and price increases.
- We believe Realtek could benefit from China's semi localization for auto Ethernet. There are no suitable local players, and Realtek has penetrated EU and US brands since 2018
- AI glasses are another secular growth driver; Realtek's AI glasses solution could drive down BOM cost 70-80% vs. the current solution from US peer Qualcomm
- We view the current 2026e P/E as fair relative to our implied target P/E of 19x.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Electric Vehicles: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BULL CASE

NT\$1,117.00

30x 2026e EPS

PC and consumer tech orders become stronger, switch/Bluetooth demand recovery comes earlier and is stronger, and higher costs and competition fade away: 1) Wi-Fi to show 30% Y/Y increase in 2026; 2) Ethernet +40% Y/Y in 2026; 3) switches to increase 40% Y/Y; 4) audio Codec +15% Y/Y; 5) gross margin goes to 52% in 2026, as margin erosion from pricing pressure is minimal.

BASE CASE

NT\$717.00

19x 2026e EPS

For 2026, we expect a modest PC decline owing to component price hikes and a GM decline from cost pass-through without markups: 1) Wi-Fi to show 17% Y/Y increase in 2026; 2) Ethernet +28% Y/Y in 2026; 3) switches to increase 24% Y/Y; 4) audio Codec +5% Y/Y; 5) gross margin declines to 48% in 2026, vs 50% in 2025.

BEAR CASE

NT\$517.00

14x 2026e EPS

PC and consumer tech orders become weaker, switch/Bluetooth demand recovery comes later and weaker; margin erosion from pricing pressure, higher costs and pricing competition becomes more severe: 1) Wi-Fi -17% Y/Y in 2026; 2) Ethernet -10% Y/Y in 2026; 3) switches flat Y/Y; 4) audio Codec -30% Y/Y; 5) gross margin declines to 48% in 2026, as margin erosion from pricing pressure intensifies.

Risk Reward – Realtek Semiconductor (2379.TW)


KEY EARNINGS INPUTS

Drivers	Dec 2025	Dec 2026e	Dec 2027e	Dec 2028e
1. Wifi Sales (%) (%)	29.3	27.5	22.5	18.8
2. Ethernet Sales (%) (%)	5.8	6.0	5.8	5.9
3. Switch Sales (%) (%)	18.1	18.1	16.4	15.1
4. Bluetooth Sales (%) (%)	6.1	5.7	4.3	3.4
5. TV SoC (%) (%)	12.9	13.0	19.2	18.8

INVESTMENT DRIVERS

- Diversifying its exposure to PCs
- Eased Wi-Fi margin pressure
- Continued growth in IoT business
- New growth driver from auto Ethernet

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

1/5
MOST

3 Month
Horizon

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Stronger-than-expected Wi-Fi growth
- Faster-than-expected new product growth
- Faster-than-expected adoption for auto Ethernet
- Fading PC semi inventory corrections

RISKS TO DOWNSIDE

- Weaker-than-expected Wi-Fi growth
- Slower-than-expected new product growth
- Slower-than-expected margin recovery given ongoing pricing competition
- Further TV SoC project losses in China
- Slower-than-expected adoption for auto Ethernet

OWNERSHIP POSITIONING

Inst. Owners, % Active 74.7%

Source: Refinitiv, Morgan Stanley Research

MS ESTIMATES VS. CONSENSUS

FY Dec 2026e

Sales / Revenue (NT\$, mn)

131,259 152,532 156,709

140,936

EBITDA (NT\$, mn)

17,826 21,468 24,716

20,899

Net income (NT\$, mn)

14,129 19,230 21,902

16,729

EPS (NT\$)

27.42 37.49 42.71

32.47

◆ Mean ◆ Morgan Stanley Estimates
Source: Refinitiv, Morgan Stanley Research

Realtek: Financial Summary

Income Statement					Cash Flow Statement				
NT\$m (Years End Dec)	2025	2026e	2027e	2028e	NT\$m (Years End Dec)	2025	2026e	2027e	2028e
Net sales	122,706	152,532	149,558	160,626	Cashflow from Operations	23,015	17,467	21,575	22,126
COGS	(61,333)	(78,947)	(75,202)	(80,848)	Net profits	14,753	19,230	19,224	22,339
Gross profit	61,374	73,585	74,356	79,777	Depreciation	1,536	1,582	1,623	1,678
Operating expenses	(47,014)	(53,639)	(53,467)	(54,635)	Working Capital Change	(3,410)	(3,345)	722	(1,892)
Operating income	14,360	19,886	20,889	25,142	Other adjustments	10,136	0	0	0
Non-operating income	2,901	2,514	1,727	1,139	Cashflow from Investing	(16,380)	(2,643)	(2,796)	(2,962)
Pre-tax income	17,261	22,400	22,616	26,282	Capex	(2,089)	(2,643)	(2,796)	(2,962)
Income tax	1,476	2,022	1,738	2,089	Change of LT Investment	(11,917)	0	0	0
Net income bf. emp. bonus	18,737	24,422	24,414	28,371	Change of ST Investment	0	0	0	0
Employee bonus expense	3,983	5,192	5,190	6,032	Other adjustments	(2,374)	0	0	0
Reported net income	14,753	19,230	19,224	22,339	Cashflow from financing	(7,616)	(12,060)	(15,719)	(15,714)
Adj. vtd. avg. shrs (million)	513	513	513	513	Increase in L/T debt	0	0	0	0
Reported EPS (NT\$)	28.77	37.49	37.48	43.56	Increase in S/T debt	5,590	0	0	0
Modelware Diluted EPS (NT\$)	28.77	37.49	37.48	43.56	Cash Dividend Paid	(13,078)	(12,060)	(15,719)	(15,714)
					Div & Emp Bonus Paid	0	0	0	0
					Issuance of stock	0	0	0	0
					Other adjustments	(128)	0	0	0
					Exchange rate adjustment	(766)	0	0	0
					Net change in cash	-1,747	2,765	3,060	3,450
Balance Sheet					Financial Ratios				
NT\$m (Years End Dec)	2025	2026e	2027e	2028e		2025	2026e	2027e	2028e
Cash	13,066	15,830	18,891	22,341	Growth(%)				
Mkt Securities	48,310	48,310	48,310	48,310	Turnover	8.2	24.3	-1.9	7.4
AR/INR	15,011	18,620	18,257	19,608	Operating profits	6.4	38.5	5.0	20.4
Inventory	19,561	21,282	20,272	21,794	Pretax profits	5.6	29.8	1.0	16.2
Other	1,409	1,409	1,409	1,409	Net profits	-3.5	30.3	0.0	16.2
Current Assets	97,357	105,451	107,139	113,462	EPS	-3.5	30.3	0.0	16.2
Long-term investments	14,175	14,175	14,175	14,175	Margins (%)				
Fixed assets	10,605	11,665	12,832	14,115	Gross Margin	50.0	48.2	49.7	49.7
Deferred assets	506	506	506	506	Operating Margin	11.7	13.0	14.0	15.7
Other assets	7,260	7,260	7,260	7,260	Pretax Margin	14.1	14.7	15.1	16.4
Total Assets	129,903	139,058	141,912	149,519	Net Profit	12.0	12.6	12.9	13.9
S/T borrowings	10,090	10,090	10,090	10,090	Return (%)				
AP/INP	11,738	13,723	13,072	14,053	ROAE	28.1	34.5	31.4	33.7
Other ST liabilities	52,328	52,328	52,328	52,328	ROAA	12.1	14.3	13.7	15.3
LT debt	0	0	0	0	Gearing (%)				
Other LT liabilities	2,935	2,935	2,935	2,935	Net Debt/Equity	(5.7)	(3.7)	(14.0)	(17.6)
Common shares	5,155	5,155	5,155	5,155	Liabilities/Equity	148.8	134.2	125.7	115.1
Total Liabilities	77,691	79,676	79,025	80,006	Ratios (X)				
Additional capital	10,506	10,506	10,506	10,506	Current ratio	1.3	1.4	1.4	1.5
Retained earning	33,733	40,303	44,408	51,033	Quick ratio	0.4	0.4	0.5	0.5
Other shareholders' equity	2,818	2,818	2,818	2,818	Others				
Total Equity	52,212	59,382	62,887	69,512	AR/INR Turnover (days)	45	45	45	45
Total Liab. & Shhldr's Equity	129,903	139,058	141,912	149,519	Inventory Turnover (days)	98	98	98	98
					AP Turnover (days)	63	63	63	63
					Cash Conversion (days)	80	80	80	80

© = Morgan Stanley Research Estimates

Source: Morgan Stanley Research, Company Data

Risk Reward Reference links

1. View explanation of Options Probabilities methodology - [Options_Probabilities_Exhibit_Link.pdf](#)
2. View descriptions of Risk Rewards Themes - [RR_Themes_Exhibit_Link.pdf](#)
3. View explanation of regional hierarchies - [GEG_Exhibit_Link.pdf](#)
4. View explanation of Theme/Exposure methodology - [ESG_Sustainable_Solutions_External_Link.pdf](#)
5. View explanation of HERS methodology - [ESG_HERS_External_Link.pdf](#)

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and their affiliates (collectively, "Morgan Stanley"). Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Charlie Chan, CFA; Daniel Yen, CFA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of June 30, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: ACM Research Inc, Advanced Micro-Fabrication Equipment Inc, Advanced Wireless Semiconductor Co, Alchip Technologies Ltd, AllRing Tech Co., AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMPT Ltd, Cambricon Technology Corporation, Dosilicon Co Ltd, FOCI Fiber Optic Communications Inc, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Hangzhou Silan Microelectronics Co. Ltd., King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, Montage Technology Co Ltd, Parade Technologies Ltd, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, SG Micro Corp., Shanghai Fudan Microelectronics, Silergy Corp., Silicon Motion, TSMC, UMC, Unigroup Guoxin Microelectronics Co Ltd, Vanguard International Semiconductor, WIN Semiconductors Corp, Winbond Electronics Corp, WPG Holdings, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Alchip Technologies Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Montage Technology Co Ltd, Powerchip Semiconductor Manufacturing Co.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from ASMPT Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Montage Technology Co Ltd, Powerchip Semiconductor Manufacturing Co.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Advanced Micro-Fabrication Equipment Inc, Alchip Technologies Ltd, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMPT Ltd, Aspeed Technology, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Hua Hong Semiconductor Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, MetaX Integrated Circuits, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, **Realtek Semiconductor**, SG Micro Corp., Shenzhen Longsys Electronics Co Ltd, SICC Co Ltd, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WinWay Technology Co Ltd, WPG Holdings, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from ASE Technology Holding Co. Ltd., King Yuan Electronics Co Ltd, MediaTek, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, **Realtek Semiconductor**, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Advanced Micro-Fabrication Equipment Inc, Alchip Technologies Ltd, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMPT Ltd, Aspeed Technology, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Hua Hong Semiconductor Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, MetaX Integrated Circuits, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, **Realtek Semiconductor**, SG Micro Corp., Shenzhen Longsys Electronics Co Ltd, SICC Co Ltd, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WinWay Technology Co Ltd, WPG Holdings, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: ASE Technology Holding Co. Ltd., Iluvatar CoreX Semiconductor Co., Ltd., King Yuan Electronics Co Ltd, MediaTek, Montage Technology Co Ltd, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, **Realtek Semiconductor**, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not

linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of June 30, 2026)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1544	42%	453	49%	29%	757	44%
Equal-weight/Hold	1577	43%	390	42%	25%	769	44%
Not-Rated/Hold	3	0%	1	0%	33%	1	0%
Underweight/Sell	544	15%	89	10%	16%	204	12%
Total	3,668		933			1731	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)

Realtek Semiconductor (2379.TW) - As of 07/30/26 GMT in TWD
Industry : Greater China Technology Semiconductors



Stock Rating History: 7/1/21 : O/I; 10/12/21 : O/C; 2/24/22 : E/C; 10/4/22 : E/A; 12/13/22 : U/A; 2/22/23 : O/I; 7/7/23 : O/A; 7/21/24 : O/I; 9/15/24 : U/I; 6/19/25 : O/I; 7/14/25 : O/A; 1/30/26 : E/A

Price Target History: 5/20/21 : 606; 7/26/21 : 666; 10/12/21 : 566; 2/24/22 : 505; 4/22/22 : 450; 7/12/22 : 333; 7/28/22 : 350; 9/13/22 : 313; 10/28/22 : 244; 12/13/22 : 239; 2/22/23 : 450; 5/30/23 : 433; 7/21/23 : 490; 10/23/23 : 470; 1/23/24 : 520; 2/1/24 : 540; 2/23/24 : 616; 3/11/24 : 707; 9/15/24 : 420; 1/14/25 : 425; 2/18/25 : 475; 6/19/25 : 650; 11/10/25 : 580; 1/30/26 : 550; 4/30/26 : 570; 7/7/26 : 717

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —
Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to <https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch>.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FCO118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 14-9169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital

Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

Morgan Stanley Hong Kong Securities Limited is the liquidity provider/market maker for securities of ASMP Ltd, GigaDevice Semiconductor Beijing Inc, Hua Hong Semiconductor Ltd, Montage Technology Co Ltd listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: <http://www.hkex.com.hk>.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: Greater China Technology Semiconductors

COMPANY (TICKER)	RATING (AS OF)	PRICE* (07/30/2026)
Charlie Chan		
ACM Research Inc (ACMR.O)	O (03/07/2023)	US\$65.30
Advanced Micro-Fabrication Equipment Inc (688012.SS)	O (11/06/2023)	Rmb346.50
Advanced Wireless Semiconductor Co (8086.TWO)	U (07/14/2025)	NT\$103.00
Alchip Technologies Ltd (3661.TW)	O (05/14/2021)	NT\$2,785.00
ASE Technology Holding Co. Ltd. (3711.TW)	O (09/15/2024)	NT\$505.00
Cambricon Technology Corporation (688256.SS)	O (04/27/2026)	Rmb1,042.43
Global Unichip Corp (3443.TW)	O (06/24/2026)	NT\$3,460.00
GlobalWafers Co Ltd (6488.TWO)	E (05/19/2026)	NT\$778.00
Gudeng Precision (3680.TWO)	O (11/25/2025)	NT\$369.50
Hua Hong Semiconductor Ltd (1347.HK)	E (03/12/2026)	HK\$125.50
Iluvatar CoreX Semiconductor Co., Ltd. (9903.HK)	O (04/27/2026)	HK\$377.00
King Yuan Electronics Co Ltd (2449.TW)	O (03/03/2023)	NT\$203.50
Maxscend Microelectronics Co Ltd (300782.SZ)	U (01/11/2021)	Rmb64.72
MediaTek (2454.TW)	O (11/28/2025)	NT\$3,235.00
MetaX Integrated Circuits (688802.SS)	E (04/27/2026)	Rmb672.00
Nanya Technology Corp. (2408.TW)	O (05/28/2026)	NT\$328.00
NAURA Technology Group Co Ltd (002371.SZ)	O (11/06/2023)	Rmb668.07
OmniVision Integrated Circuits Group Inc (603501.SS)	E (11/17/2025)	Rmb88.50
Phison Electronics Corp (8299.TWO)	E (02/25/2026)	NT\$1,495.00
SG Micro Corp. (300661.SZ)	E (11/03/2025)	Rmb89.58
Silergy Corp. (6415.TW)	U (05/19/2026)	NT\$375.50
SMIC (0981.HK)	O (10/21/2025)	HK\$62.00
TSMC (2330.TW)	O (02/07/2022)	NT\$2,205.00
UMC (2303.TW)	O (05/19/2026)	NT\$110.00
Vanguard International Semiconductor (5347.TWO)	E (01/14/2026)	NT\$138.00
WIN Semiconductors Corp (3105.TWO)	U (07/14/2025)	NT\$268.00

Daisy Dai, CFA

ASMP Ltd (0522.HK)	O (07/24/2025)	HK\$135.10
China Resources Microelectronics Limited (688396.SS)	U (03/02/2026)	Rmb53.79
Empyrean Technology Co Ltd (301269.SZ)	E (01/17/2025)	Rmb85.49
Hangzhou Silan Microelectronics Co. Ltd. (600460.SS)	U (08/25/2025)	Rmb27.77
Hygon Information Technology Co., Ltd. (688041.SS)	O (07/03/2026)	Rmb273.42
Innoscence (2577.HK)	E (10/13/2025)	HK\$36.94
JCET Group Co Ltd (600584.SS)	E (01/16/2026)	Rmb64.51
Shanghai Fudan Microelectronics (1385.HK)	O (03/07/2025)	HK\$22.52
SICC Co Ltd (688234.SS)	O (03/20/2026)	Rmb81.35
StarPower Semiconductor Ltd (603290.SS)	E (05/14/2026)	Rmb79.08
Unigroup Guoxin Microelectronics Co Ltd (002049.SZ)	U (01/10/2023)	Rmb64.70
Universal Scientific Ind. (Shanghai) (601231.SS)	O (11/05/2025)	Rmb21.49
Yangjie Technology (300373.SZ)	O (06/10/2022)	Rmb81.93

Daniel Yen, CFA

AP Memory Technology Corp (6531.TW)	O (07/11/2025)	NT\$607.00
ASMedia Technology Inc (5269.TW)	U (10/03/2025)	NT\$1,305.00
Aspeed Technology (5274.TWO)	O (06/09/2025)	NT\$13,205.00
Egis Technology Inc (6462.TWO)	E (01/28/2026)	NT\$88.00
Elan Microelectronics Corp (2458.TW)	O (10/03/2025)	NT\$148.00
Espressif Systems (688018.SS)	O (05/15/2023)	Rmb91.88
GigaDevice Semiconductor Beijing Inc (603986.SS)	O (05/15/2025)	Rmb371.10
Macronix International Co Ltd (2337.TW)	O (09/18/2025)	NT\$91.80
Montage Technology Co Ltd (6809.HK)	O (03/18/2026)	HK\$251.40
Montage Technology Co Ltd (688008.SS)	O (03/18/2026)	Rmb196.78
Novatek (3034.TW)	U (02/04/2026)	NT\$491.00
Nuvoton Technology Corporation (4919.TW)	U (11/10/2025)	NT\$106.50
Parade Technologies Ltd (4966.TWO)	O (05/27/2026)	NT\$532.00
Powerchip Semiconductor Manufacturing Co (6770.TW)	O (10/27/2025)	NT\$49.55
Realtek Semiconductor (2379.TW)	E (01/30/2026)	NT\$697.00
Shenzhen Goodix Technology Co Ltd (603160.SS)	U (07/14/2025)	Rmb52.23
Winbond Electronics Corp (2344.TW)	O (05/28/2026)	NT\$118.50
WPG Holdings (3702.TW)	O (03/16/2026)	NT\$105.50
WT Microelectronics Co. Ltd. (3036.TW)	O (01/27/2026)	NT\$183.50

Duan Liu

Dosilicon Co Ltd (688110.SS)	U (09/06/2024)	Rmb101.52
Shenzhen Longsys Electronics Co Ltd (301308.SZ)	E (02/25/2026)	Rmb338.78

Tiffany Yeh

AllRing Tech Co. (6187.TWO)	O (09/23/2025)	NT\$845.00
FOCI Fiber Optic Communications Inc (3363.TWO)	O (01/15/2025)	NT\$437.00
Himax Technologies Inc (HIMX.O)	E (02/04/2026)	US\$11.64
Hon Precision (7769.TW)	O (04/17/2026)	NT\$5,620.00
MPI Corporation (6223.TWO)	O (04/17/2026)	NT\$4,800.00
Silicon Motion (SIMO.O)	O (05/06/2024)	US\$209.68
WinWay Technology Co Ltd (6515.TW)	O (04/17/2026)	NT\$5,290.00

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.